Published Data in Hepatocellular Carcinoma
Selective Internal Radiation Therapy (SIRT) with SIR-Spheres® Y-90 resin microspheres has shown to improve survival in patients with hepatocellular carcinoma (HCC).
In the first-line setting, SIR-Spheres Y-90 resin microspheres significantly improved Overall Surival (OS) by 8 months compared with matched controls receiving active treatment or supportive care in patients with unresectable advanced HCC.1
The largest multicentre analysis of SIR-Spheres Y-90 resin microspheres in HCC included first-line and second-line treatment in 325 patients with advanced HCC (ENRY trial).2 All patients received SIR-Spheres Y-90 resin microspheres, and the authors noted the following:
- Survival outcomes compared favourably with transarterial chemoembolisation (TACE)/transarterial embolisation (TAE) for unresectable patients in Barcelona Clinic Liver Cancer (BCLC) stages A and B.
- Benefits of SIR-Spheres Y-90 resin microspheres treatment were particularly favourable for patients with intermediate, BCLC stage B disease who were poor candidates for TACE or had failed TACE/TAE.
- SIR-Spheres Y-90 resin microspheres also showed positive results in patients with advanced stage (BCLC stage C) disease, particularly those with portal vein thrombosis (PVT).
Importantly, OS benefits are observed with first-line or second-line use of SIR-Spheres Y-90 resin microspheres, irrespective of patient age, presence or absence of PVT, and whether or not the patient has had a previous procedure.2-5
Survival and progression outcomes with first- or second-line SIR-Spheres Y-90 resin microspheres in intermediate to advanced stage HCC compare favourably with TACE/TAE,2,6-7 and sorafenib,2 with no negative impact on health-related Quality of Life.6
An additional benefit of SIR-Spheres Y-90 resin microspheres is down-staging HCC to potentially curative resection and bridiging some patients to transplant .3,4,8,9 These effects can reduce the burden of the disease on the patient, and with down-staging to allow for subsequent curative treatment, the burden on the healthcare systems can be reduced in the longer term.
1 D'Avola D et al. Hepatogastroenterology 2009; 56: 1683-1688.
2 Sangro B et al. Hepatology 2011; 54: 868-878.
3 Inarrairaegui M et al. Int J Radiat Oncol Biol Phys 2010; 77: 1441-1448.
4 Lau WY et al. Int J Radiat Oncol Biol Phys 1998; 40: 583-592.
5 Golfieri R et al. J Hepatol 2013; 59: 753-761.
6 Kolligs F et al. Liver Int 2015; 35: 1715-1721.
7 Soydal C et al. Nucl Med Commun 2016; 37: 646-649.
8 Gramenzi A et al. Liver Int 2015; 35: 1036-104.
9 Ettorre GM et al. World J Surg 2016 Aug 5; ePub doi: 10.1007/s00268-016-3682-z.